HLTRF News and Press, HLS Therapeutics Inc From 11/07/19

HLS Therapeutics Announces Q3 2019 Financial Results Canada NewsWire TORONTO, Nov. 7, 2019 Revenue of $13.4 million , Adjusted EBITDA of $8.0 million and Cash from Operations of $6.8 million Paid a quarterly dividend of C$0.05 per outstanding common share Su...

HLS Therapeutics to Host Q3 2019 Financial Results Conference Call Canada NewsWire TORONTO, Oct. 24, 2019 TORONTO , Oct. 24, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company specializing in central nervous system a...

HLS Therapeutics ( OTCPK:HLTRF ) announces that Health Canada has granted a medical device license for the Athelas One WBC System for use as a point-of-care device indicated for quantitative determination of white blood cells and neutrophil percentages in capillary or venous whole blood. ...

HLS Therapeutics announces Health Canada grants medical device license for White Blood Cell Point-of-Care Device to be marketed as CSAN® PRONTO™ Canada NewsWire TORONTO, Oct. 17, 2019 From a single drop of blood from the tip of a finger, Athelas One WBC System...

HLS Therapeutics ( OTCPK:HLTRF ): Q2 GAAP EPS of -$0.06 misses by $0.01 . More news on: HLS Therapeutics Inc., Earnings news and commentary, Tech stocks news, Read more ...

HLS Therapeutics Announces Q2 2019 Financial Results Canada NewsWire TORONTO, Aug. 8, 2019 Revenue of $13.6 million , Adjusted EBITDA of $8.1 million and Cash from Operations of $9.0 million Filed the New Drug Submission for Vascepa® with Health Canada after ...

HLS Therapeutics to Host Q2 2019 Financial Results Conference Call Canada NewsWire TORONTO, July 25, 2019 TORONTO , July 25, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company specializing in central nervous sy...

HLS Therapeutics Reports Annual Meeting Results Canada NewsWire TORONTO, June 21, 2019 TORONTO , June 21, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS) announces voting results from its Annual Meeting of Shareholders held on June 21, 2019 in To...

HLS Therapeutics ( OTCPK:HLTRF ): Q1 GAAP EPS of -$0.14. More news on: HLS Therapeutics Inc., Earnings news and commentary, Tech stocks news, Read more ...

Health Canada grants priority review status for Amarin's (NASDAQ: AMRN ) licensee, HLS Therapeutics' ( OTCPK:HLTRF ) New Drug Submission (“NDS”) for Vascepa (icosapent ethyl) capsules. More news on: Amarin Corporation plc, HLS Therapeutics Inc., Healthcare stocks news, ...